ADXN Valuation Metrics
FCF$-5.97M
FCF Growth Rate—
EPS Growth (CAGR)—
WACC10.00%
Addex Therapeutics Ltd
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Values in USD · ADR · Reports in CHF
Addex Therapeutics Ltd ADS
Did you know?
Price sits at 25% of its 52-week range.
Current Price
$7.00
+0.57%Profile
Valuation (TTM)
Market Cap$5.51M
P/E-0.71
EV—
P/B0.51
Shares Out786589.60
P/Sales29.17
Revenue$188779.63
EV/EBITDA—
Addex Therapeutics Ltd (ADXN) Valuation
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →ADXN Valuation & Fair Value Analysis
Addex Therapeutics Ltd (ADXN) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The price-to-earnings (P/E) ratio is -0.71. Price-to-book ratio is 0.51. Price-to-sales ratio is 29.17. PEG ratio is 0.01.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Addex Therapeutics Ltd's intrinsic value.